Literature DB >> 31555515

Quantitative features of dual-energy spectral computed tomography for solid lung adenocarcinoma with EGFR and KRAS mutations, and ALK rearrangement: a preliminary study.

Meng Li1, Li Zhang1, Wei Tang1, Pei-Qing Ma2, Li-Na Zhou1, Yu-Jing Jin1, Lin-Lin Qi1, Ning Wu1,3.   

Abstract

BACKGROUND: The present work aimed to evaluate radio-genomic associations of quantitative parameters obtained by dual-energy spectral computed tomography (DESCT) for solid lung adenocarcinoma with epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations, as well as anaplastic lymphoma kinase (ALK) rearrangement.
METHODS: Ninety-six cases of solid lung cancer were selected and assessed for EGFR and KRAS mutations, and ALK rearrangement. Then, they underwent chest DESCT, and quantitative parameters, including water concentration (WC), iodine concentration (IC), CT value at 70 keV, effective atomic number (Effective-Z) and spectral Hounsfield unit curve slope (λHU slope) were measured. Finally, the associations of quantitative radiological features with various gene alterations were evaluated.
RESULTS: The positive rates were 51.0% (49/96) for EGFR, 13.5% (13/96) for KRAS and 16.7% (16/96) for ALK. In univariate analysis, EGFR mutation was associated with smoking status, CT value at 70 keV, IC, Effective-Z, and λHU slope; KRAS mutation was associated with CT value at 70 keV, IC, Effective-Z, and λHU slope, and ALK rearrangement was correlated with age and WC. In multivariate analysis, smoking status (OR =2.924, P=0.019) and CT value at 70 keV (OR =1.036, P=0.006) were significantly associated with EGFR mutation; Effective-Z and age were significantly associated with KRAS mutation (OR =0.047, P=0.032) and ALK rearrangement (OR =0.933, P=0.008), respectively.
CONCLUSIONS: Quantitative analysis of DESCT could help detect solid lung adenocarcinoma harboring EGFR or KRAS mutation, or ALK rearrangement.

Entities:  

Keywords:  ALK; Dual-energy spectral computed tomography (DESCT); EGFR; KRAS; lung adenocarcinoma

Year:  2019        PMID: 31555515      PMCID: PMC6749133          DOI: 10.21037/tlcr.2019.08.13

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  52 in total

1.  Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung.

Authors:  Hiroshi Haneda; Hidefumi Sasaki; Shigeki Shimizu; Katsuhiko Endo; Eriko Suzuki; Haruhiro Yukiue; Yoshihiro Kobayashi; Motoki Yano; Yoshitaka Fujii
Journal:  Lung Cancer       Date:  2006-02-28       Impact factor: 5.705

Review 2.  Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers.

Authors:  Hisayuki Shigematsu; Adi F Gazdar
Journal:  Int J Cancer       Date:  2006-01-15       Impact factor: 7.396

3.  The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

Authors:  Daisy Wing-Sze Wong; Elaine Lai-Han Leung; Kimpton Kam-Ting So; Issan Yee-San Tam; Alan Dart-Loon Sihoe; Lik-Cheung Cheng; Kwok-Keung Ho; Joseph Siu-Kie Au; Lap-Ping Chung; Maria Pik Wong
Journal:  Cancer       Date:  2009-04-15       Impact factor: 6.860

4.  Pulmonary adenocarcinomas: classification and reporting.

Authors:  Keith M Kerr
Journal:  Histopathology       Date:  2009-01       Impact factor: 5.087

Review 5.  Reporting lung cancer pathology specimens. Impact of the anticipated 7th Edition TNM classification based on recommendations of the IASLC Staging Committee.

Authors:  William D Travis
Journal:  Histopathology       Date:  2009-01       Impact factor: 5.087

6.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

7.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

8.  Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Authors:  Manabu Soda; Young Lim Choi; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Shunpei Ishikawa; Shin-ichiro Fujiwara; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Masashi Bando; Shoji Ohno; Yuichi Ishikawa; Hiroyuki Aburatani; Toshiro Niki; Yasunori Sohara; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Nature       Date:  2007-07-11       Impact factor: 49.962

Review 9.  AKT/PKB signaling: navigating downstream.

Authors:  Brendan D Manning; Lewis C Cantley
Journal:  Cell       Date:  2007-06-29       Impact factor: 41.582

Review 10.  Hypoxia-inducible factors: central regulators of the tumor phenotype.

Authors:  John D Gordan; M Celeste Simon
Journal:  Curr Opin Genet Dev       Date:  2007-01-08       Impact factor: 5.578

View more
  8 in total

1.  Dual-energy computed tomography for pre-surgical identification of adenocarcinoma subtypes.

Authors:  Claudia I Henschke
Journal:  Transl Lung Cancer Res       Date:  2020-06

2.  Evaluating Solid Lung Adenocarcinoma Anaplastic Lymphoma Kinase Gene Rearrangement Using Noninvasive Radiomics Biomarkers.

Authors:  De-Ning Ma; Xin-Yi Gao; Yi-Bo Dan; An-Ni Zhang; Wei-Jun Wang; Guang Yang; Hong-Zhou Zhu
Journal:  Onco Targets Ther       Date:  2020-07-16       Impact factor: 4.147

3.  Epidermal growth factor receptor mutations in lung adenocarcinoma: associations between dual-energy spectral CT measurements and histologic results.

Authors:  Guojin Zhang; Junlin Zhou; Yuntai Cao; Jing Zhang; Zhiyong Zhao; Wenjuan Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2020-09-26       Impact factor: 4.553

4.  Dual-energy CT quantitative parameters for the differentiation of benign from malignant lesions and the prediction of histopathological and molecular subtypes in breast cancer.

Authors:  Xiaoxia Wang; Daihong Liu; Xiangfei Zeng; Shixi Jiang; Lan Li; Tao Yu; Jiuquan Zhang
Journal:  Quant Imaging Med Surg       Date:  2021-05

5.  Dual-energy CT quantitative parameters for evaluating Immunohistochemical biomarkers of invasive breast cancer.

Authors:  Xiaoxia Wang; Daihong Liu; Xiangfei Zeng; Shixi Jiang; Lan Li; Tao Yu; Jiuquan Zhang
Journal:  Cancer Imaging       Date:  2021-01-07       Impact factor: 3.909

Review 6.  Radiomics/Radiogenomics in Lung Cancer: Basic Principles and Initial Clinical Results.

Authors:  Athanasios K Anagnostopoulos; Anastasios Gaitanis; Ioannis Gkiozos; Emmanouil I Athanasiadis; Sofia N Chatziioannou; Konstantinos N Syrigos; Dimitris Thanos; Achilles N Chatziioannou; Nikolaos Papanikolaou
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

7.  Application of dual-energy computed tomography in preoperative evaluation of Ki-67 expression levels in solid non-small cell lung cancer.

Authors:  Shuangfeng Tian; Xia Jianguo; Weizhong Tian; Yuan Li; Jianfeng Hu; Mingjun Wang; Juntao Zhang
Journal:  Medicine (Baltimore)       Date:  2022-08-05       Impact factor: 1.817

8.  Application of Dual-Energy Spectral Computed Tomography in Bone Mineral Density Measurement: Phantom and Clinical Research.

Authors:  Mingyue Wang; Yan Wu; Yue Zhou; Junqiang Dong; Shenshen Hu; Ping Hou; Jianbo Gao
Journal:  Int J Gen Med       Date:  2022-08-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.